• Product
• Opening of FAPA (The Federation of Asian Pharmaceutical Asso
• by Kim JiEun Nov 11, 2022 05:52am

• Product
• KMA proposes preconditions for non-face-to-face treatment
• by Kang, Shin-Kook Nov 11, 2022 05:52am

• Company
• Daewoong obtained an item license for Fexuclu
• by Nov 11, 2022 05:52am

• Company
• SK Biopharm’s Q3 sales rise 270% with rise in Xcopri sales
• by Nov 11, 2022 05:51am

• Policy
• Some companies give up negotiations to recover Strepto
• by Lee, Tak-Sun Nov 11, 2022 05:51am

• Company
• Impinzi's indication is expected to be approved in Korea
• by Eo, Yun-Ho Nov 10, 2022 05:46am

• Policy
• Will expedited listing be possible within the year?
• by Lee, Tak-Sun Nov 10, 2022 05:46am

• Company
• Samjin-Pin to co-develop new targeted protein degrader
• by Lee, Seok-Jun Nov 10, 2022 05:46am

• Opinion
• [Reporter's view] COVID-19 demand has disappeared
• by Nov 10, 2022 05:45am

• Policy
• We will do our best to compensate for Paxlovid side effects
• by Lee, Jeong-Hwan Nov 10, 2022 05:45am